UNH UnitedHealth Group
Margin repair is ahead of schedule, but a regulated 6% ceiling still leaves price above value.
The story
UnitedHealth is the largest US managed-care and health-services platform, pairing UnitedHealthcare's insurance scale with Optum's care-delivery, PBM and data businesses in a vertically integrated loop that peers cannot easily copy. It is a mature franchise growing with healthcare spending. The 2024-2025 margin collapse came from elevated medical cost trend, Medicare Advantage rate pressure, and regulatory and DOJ scrutiny of the Optum integration. TTM operating margin has recovered to 5.2% from 4.2%, so the repair is real, but rate regulation and political risk cap how far it can go.
TTM operating margin has already reached 5.2%, close to my prior 5.5% target. So I am raising the target modestly to 6.0% (a 9% relative move, not material) and shortening margin_years from 6 to 5 because the repair is arriving faster than I expected. That 6.0% is still well below the 8.7% peak, because MA rate pressure, PBM reform and Optum vertical-integration scrutiny make the old margins unlikely to come back. All other drivers stay the same: growth tracks healthcare spending, reinvestment efficiency matches the observed 2.61, and the 8-year horizon fits a scaled but regulated franchise.
Value drivers
| Revenue growth (Y1) | 5.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 6.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.60 |
| Beta | 1.05 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 101.69B |
| PV of terminal value | 223.72B |
| Equity value | 255.89B |
| ÷ shares → per share | $285.58 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 474.39B | 5.5% | 5.4% | 22.31B | 9.51B | 12.80B | 11.73B |
| 2 | 499.13B | 5.2% | 5.5% | 24.13B | 9.51B | 14.61B | 12.27B |
| 3 | 523.73B | 4.9% | 5.7% | 26.01B | 9.46B | 16.54B | 12.73B |
| 4 | 548.05B | 4.6% | 5.8% | 27.93B | 9.35B | 18.58B | 13.11B |
| 5 | 571.92B | 4.4% | 6.0% | 29.90B | 9.18B | 20.72B | 13.39B |
| 6 | 595.21B | 4.1% | 6.0% | 31.12B | 8.96B | 22.16B | 13.13B |
| 7 | 617.74B | 3.8% | 6.0% | 32.30B | 8.67B | 23.63B | 12.83B |
| 8 | 639.36B | 3.5% | 6.0% | 33.43B | 8.32B | 25.11B | 12.49B |
Key risks
- Medicare Advantage rate notices and risk-adjustment (V28) changes compress UnitedHealthcare margins further
- DOJ or legislative action forcing structural separation of Optum or PBM reform hitting OptumRx economics
- Medical cost trend staying elevated, so pricing lags utilization for another cycle
Catalysts
- Medical care ratio normalization showing up in 2027 guidance and repricing of MA bids
- Favorable 2027-2028 CMS final rate notices or resolution of DOJ investigations